XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Payment Arrangement, Option, Activity
The following table summarizes the Company’s stock option activity and related information under all equity plans, excluding performance and market awards:
Number of OptionsWeighted-Average Exercise PriceWeighted-Average
Remaining Contractual Life (Years)
Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2022
4,191,426 $3.18 9.1$
Granted2,794,596 $1.64 
Forfeited(411,588)$3.55 
Outstanding at June 30, 2023
6,574,434 $2.50 9.0$
Vested and exercisable at June 30, 2023
1,247,904 $3.63 7.9$
Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option
Number of OptionsWeighted-Average Exercise PriceWeighted-Average
Remaining Contractual Life (Years)
Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2022
5,368,501 $9.92 9.0$— 
Forfeited(201,952)$9.92 
Outstanding at June 30, 2023
5,166,549 $9.92 8.4$— 
Vested and exercisable at June 30, 2023
1,436,378 $9.92 8.1$— 
The following table summarizes the Company’s restricted stock units activity and related information under all equity plans:
Number of Restricted Stock UnitsWeighted-Average Grant Date Fair Value
Outstanding at December 31, 2022
447,948 $2.50 
Forfeited(112,064)$2.50 
Outstanding at June 30, 2023
335,884 $2.50 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions
The assumptions used to determine the grant date fair value of non-market based, stock options granted were as follows, presented on a weighted-average basis:
Six Months Ended June 30,
20232022
Expected term (in years)5.95.8
Expected volatility83%78%
Risk-free interest rate3.5%3.0%
Dividend yield
Share-Based Payment Arrangement, Expensed and Capitalized, Amount
Total stock-based compensation expense was as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
General and administrative$3,081 $7,863 $6,320 $8,322 
Research and development353 1,362 877 1,564 
Total stock-based compensation expense$3,434 $9,225 $7,197 $9,886